Zoetis Inc. $ZTS Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. cut its stake in Zoetis Inc. (NYSE:ZTS) by 8.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 116,275 shares of the company’s stock after selling 11,310 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $8,356,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. VELA Investment Management LLC boosted its position in shares of Zoetis by 49.0% in the second quarter. VELA Investment Management LLC now owns 23,134 shares of the company’s stock worth $1,662,000 after buying an additional 7,606 shares during the period. Hohimer Wealth Management LLC purchased a new stake in shares of Zoetis during the 2nd quarter valued at about $4,012,000. Tema ETFs LLC raised its holdings in shares of Zoetis by 18.9% during the 2nd quarter. Tema ETFs LLC now owns 8,984 shares of the company’s stock valued at $646,000 after buying an additional 1,431 shares during the period. Handelsbanken Fonder AB lifted its position in Zoetis by 10.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 228,467 shares of the company’s stock worth $16,418,000 after acquiring an additional 21,990 shares in the last quarter. Finally, Fulton Bank N.A. lifted its position in Zoetis by 6.1% during the 2nd quarter. Fulton Bank N.A. now owns 11,366 shares of the company’s stock worth $817,000 after acquiring an additional 652 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Piper Sandler lowered their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Finally, Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $109.62.

Zoetis Trading Down 2.9%

Shares of ZTS opened at $73.64 on Friday. Zoetis Inc. has a one year low of $71.45 and a one year high of $160.48. The stock has a 50-day moving average price of $76.30 and a 200 day moving average price of $99.01. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $30.43 billion, a P/E ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the business earned $1.76 EPS. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.19 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.